XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.2

Segment Information (Tables)

6 Months Ended

Jun. 30, 2023

Segment Information [Abstract]

Schedule of Segment Information

we operate in the following two reportable business segments:

		During the Three-Month Period Ended June 30, 2023
		Scours				Mastitis				Other				Total
Product sales		$	3,482,259			$	50,422			$	—			$	3,532,681
Costs of goods sold			2,453,169				35,624				—				2,488,793
Gross margin			1,029,090				14,798				—				1,043,888
Product development expenses			2,252				1,061,383				35,903				1,099,538
Sales and marketing expenses			558,179				161,610				—				719,789
Administrative expenses			—				—				529,056				529,056
Operating expenses			560,431				1,222,993				564,959				2,348,383
NET OPERATING INCOME (LOSS)		$	468,659			$	(1,208,195	)		$	(564,959	)		$	(1,304,495	)

		During the Three-Month Period Ended June 30, 2022
		Scours				Mastitis				Other				Total
Product sales		$	3,823,466			$	37,834			$	72			$	3,861,372
Costs of goods sold			2,119,194				31,848				3,002				2,154,044
Gross margin			1,704,272				5,986				(2,930	)			1,707,328
Product development expenses			8,188				1,102,939				27,640				1,138,767
Sales and marketing expenses			339,570				319,669				—				659,239
Administrative expenses			—				—				528,329				528,329
Operating expenses			347,758				1,422,608				555,969				2,326,335
NET OPERATING INCOME (LOSS)		$	1,356,514			$	(1,416,622	)		$	(558,899	)		$	(619,007	)

		Scours				Mastitis				Other				Total
Total Assets as of June 30, 2023		$	23,910,633			$	18,374,662			$	1,721,773			$	44,007,068
Total Assets as of June 30, 2022		$	15,897,359			$	18,833,556			$	11,252,934			$	45,983,849
Depreciation and amortization expense during the three-month period ended June 30, 2023		$	341,979			$	323,661			$	21,074			$	686,714
Depreciation and amortization expense during the three-month period ended June 30, 2022		$	299,829			$	315,742			$	15,728			$	631,299
Capital Expenditures during the three-month period ended June 30, 2023		$	124,911			$	583,577			$	—			$	708,488
Capital Expenditures during the three-month period ended June 30, 2022		$	657,561			$	285,729			$	—			$	943,290

		During the Six-Month Period Ended June 30, 2023
		Scours				Mastitis				Other				Total
Product sales		$	6,893,491			$	85,716			$	—			$	6,979,207
Costs of goods sold			5,557,127				77,417				—				5,634,544
Gross margin			1,336,364				8,299				—				1,344,663
Product development expenses			2,543				2,137,728				69,636				2,209,907
Sales and marketing expenses			1,248,723				350,493				—				1,599,216
Administrative expenses			—				—				1,096,074				1,096,074
Operating expenses			1,251,266				2,488,221				1,165,710				4,905,197
NET OPERATING INCOME (LOSS)		$	85,098			$	(2,479,922	)		$	(1,165,710	)		$	(3,560,534	)

		During the Six-Month Period Ended June 30, 2022
		Scours				Mastitis				Other				Total
Product sales		$	9,786,341			$	73,261			$	1,454			$	9,861,056
Costs of goods sold			4,971,523				58,651				20,331				5,050,505
Gross margin			4,814,818				14,610				(18,877	)			4,810,551
Product development expenses			16,604				2,085,068				73,030				2,174,702
Sales and marketing expenses			758,238				712,502				—				1,470,740
Administrative expenses			—				—				1,213,508				1,213,508
Operating expenses			774,842				2,797,570				1,286,538				4,858,950
NET OPERATING INCOME (LOSS)		$	4,039,976			$	(2,782,960	)		$	(1,305,415	)		$	(48,399	)

		Scours				Mastitis				Other				Total
Total Assets as of June 30, 2023		$	23,910,633			$	18,374,662			$	1,721,773			$	44,007,068
Total Assets as of June 30, 2022		$	15,897,359			$	18,833,556			$	11,252,934			$	45,983,849
Depreciation and amortization expense during the six-month period ended June 30, 2023		$	665,236			$	641,285			$	39,022			$	1,345,543
Depreciation and amortization expense during the six-month period ended June 30, 2022		$	592,621			$	630,750			$	31,456			$	1,254,827
Capital Expenditures during the six-month period ended June 30, 2023		$	696,647			$	694,007			$	—			$	1,390,654
Capital Expenditures during the six-month period ended June 30, 2022		$	1,384,282			$	366,504			$	—			$	1,750,786

		During the Year Ended December 31, 2022
		Scours				Mastitis				Other				Total
Product sales		$	18,411,949			$	154,558			$	1,455			$	18,567,962
Costs of goods sold			10,754,189				136,347				28,647				10,919,183
Gross margin			7,657,760				18,211				(27,192	)			7,648,779
Product development expenses			66,346				4,317,921				109,605				4,493,872
Sales and marketing expenses			1,871,926				1,318,107				—				3,190,033
Administrative expenses			—				—				2,263,817				2,263,817
Operating expenses			1,938,272				5,636,028				2,373,422				9,947,722
NET OPERATING INCOME (LOSS)		$	5,719,488			$	(5,617,817	)		$	(2,400,614	)		$	(2,298,943	)

		During the Year Ended December 31, 2021
		Scours				Mastitis				Other				Total
Product sales		$	18,933,092			$	143,280			$	166,597			$	19,242,969
Costs of goods sold			10,411,936				99,957				75,147				10,587,040
Gross margin			8,521,156				43,323				91,450				8,655,929
Product development expenses			25,374				3,887,781				255,363				4,168,518
Sales and marketing expenses			1,942,391				561,535				—				2,503,926
Administrative expenses			—				—				1,726,100				1,726,100
Operating expenses			1,967,765				4,449,316				1,981,463				8,398,544
NET OPERATING INCOME (LOSS)		$	6,553,391			$	(4,405,993	)		$	(1,890,013	)		$	257,385

		Scours				Mastitis				Other				Total
Total Assets as of December 31, 2022		$	20,539,523			$	18,315,492			$	6,005,634			$	44,860,649
Total Assets as of December 31, 2021		$	14,860,769			$	19,122,265			$	10,482,654			$	44,465,688
Depreciation and amortization expense during the year ended December 31, 2022		$	1,169,011			$	1,263,318			$	62,912			$	2,495,241
Depreciation and amortization expense during the year ended December 31, 2021		$	1,032,735			$	1,374,171			$	62,075			$	2,468,981
Capital Expenditures during the year ended December 31, 2022		$	3,513,336			$	414,486			$	47,452			$	3,975,274
Capital Expenditures during the year ended December 31, 2021		$	1,632,855			$	975,794			$	—			$	2,608,649

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-25

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration